Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Impacted by end of agrements in LATAM- is this only Gilead ?

<< Previous

Bullboard Posts

Next >>

Comment by Snowballgrowthon Nov 19, 2022 7:40am

97 Views

Post# 35112367

RE:RE:Impacted by end of agrements in LATAM- is this only Gilead ?

gudisgood wrote: There were a few factors offsetting growth this quarter:

No covid sales and no Gilead sales ($10.5M)

Lower levels of Exelon sales due to advande buying in the last quarter ($2M)

Lower levels of branded generics sales due to new competition

Out of these, I would consider the branded generics a negative... but it's difficult to say how significant it is. I wish someone would have asked about this during the call.

If we look at the numbers by therapeutic area:

Oncology grew nicely (key products) especially when you consider the growth was offset by whatever decline we had from branded generics. Key products grew at least 14% (plus whatever the decline from branded generics was).

Infectious Diseases had great growth if you exclude covid and Gilead sales from last year's numbers. It went from $20.5M to $27.3M = 33% growth!

Seems like Exelon sales were basically the same as last year if you take the $2M of advance sales into account. Hopefully they can start achieving growth here now that they've been handed the keys.

A good level of operating cash flow, by the way, even with a $4M+ increase in working capital (with a further increase expected during the ongoing quarter).